Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1992 1
1994 2
1996 2
1997 1
1998 1
2000 1
2001 2
2002 1
2003 1
2007 1
2008 1
2011 1
2017 1
2019 1
2020 2
2021 2
2022 2
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M. Arend R, et al. Among authors: sirard ca. Gynecol Oncol. 2023 May;172:82-91. doi: 10.1016/j.ygyno.2023.03.013. Epub 2023 Mar 29. Gynecol Oncol. 2023. PMID: 37001446 Clinical Trial.
Rational design of anti-GITR-based combination immunotherapy.
Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, Yang X, Zhong H, Newman W, Qi J, Wong P, Schaer D, Koon H, Velcheti V, Hellmann MD, Postow MA, Callahan MK, Wolchok JD, Merghoub T. Zappasodi R, et al. Among authors: sirard c. Nat Med. 2019 May;25(5):759-766. doi: 10.1038/s41591-019-0420-8. Epub 2019 Apr 29. Nat Med. 2019. PMID: 31036879 Free PMC article. Clinical Trial.
Response to anti-DKK1 therapy in uterine carcinosarcoma: A case report.
ElNaggar A, Zhang N, Scalise CB, Sirard C, Kagey MH, Vaena D, Arend R. ElNaggar A, et al. Among authors: sirard c. Gynecol Oncol Rep. 2021 Dec 9;39:100904. doi: 10.1016/j.gore.2021.100904. eCollection 2022 Feb. Gynecol Oncol Rep. 2021. PMID: 35531363 Free PMC article.
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.
Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J, Holland A, Wong P, Sifferlen L, Piper D, Sirard CA, Merghoub T, Wolchok JD, Luke JJ. Davar D, et al. Among authors: sirard ca. Clin Cancer Res. 2022 Sep 15;28(18):3990-4002. doi: 10.1158/1078-0432.CCR-22-0339. Clin Cancer Res. 2022. PMID: 35499569 Free PMC article.
Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer.
Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, Thoren KL, Abida W, Sfanos KS, De Marzo AM, Yegnasubramanian S, Fox JJ, Haas M, Heath H, Kagey MH, Newman W, Sirard CA, Fleisher M, Morris MJ, Chen Y, Larson SM, Haffner MC, Nelson PS, Schultz N, Garabedian MJ, Scher HI, Logan SK, Sawyers CL; International SU2C/PCF Prostate Cancer Dream Team. Wise DR, et al. Among authors: sirard ca. JCO Precis Oncol. 2020 Sep 29;4:PO.20.00097. doi: 10.1200/PO.20.00097. eCollection 2020. JCO Precis Oncol. 2020. PMID: 33015525 Free PMC article.
Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.
Klempner SJ, Bendell JC, Villaflor VM, Tenner LL, Stein SM, Rottman JB, Naik GS, Sirard CA, Kagey MH, Chaney MF, Strickler JH. Klempner SJ, et al. Among authors: sirard ca. Mol Cancer Ther. 2021 Nov;20(11):2240-2249. doi: 10.1158/1535-7163.MCT-21-0273. Epub 2021 Sep 4. Mol Cancer Ther. 2021. PMID: 34482288 Free PMC article. Clinical Trial.
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Wise DR, Pachynski RK, Denmeade SR, Aggarwal RR, Deng J, Febles VA, Balar AV, Economides MP, Loomis C, Selvaraj S, Haas M, Kagey MH, Newman W, Baum J, Troxel AB, Griglun S, Leis D, Yang N, Aranchiy V, Machado S, Waalkes E, Gargano G, Soamchand N, Puranik A, Chattopadhyay P, Fedal E, Deng FM, Ren Q, Chiriboga L, Melamed J, Sirard CA, Wong KK. Wise DR, et al. Among authors: sirard ca. Prostate Cancer Prostatic Dis. 2024 Feb 10. doi: 10.1038/s41391-024-00798-z. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38341461
Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer.
Goyal L, Sirard C, Schrag M, Kagey MH, Eads JR, Stein S, El-Khoueiry AB, Manji GA, Abrams TA, Khorana AA, Miksad R, Mahalingam D, Zhu AX, Duda DG. Goyal L, et al. Among authors: sirard c. Clin Cancer Res. 2020 Dec 1;26(23):6158-6167. doi: 10.1158/1078-0432.CCR-20-1310. Epub 2020 Sep 2. Clin Cancer Res. 2020. PMID: 32878766 Clinical Trial.
27 results